^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR7390

    i
    Other names: SHR7390, SHR 7390
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    MEK1 inhibitor, MEK2 inhibitor
    Related drugs:
    over1year
    SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=6, Completed, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting --> Completed | N=10 --> 6 | Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: Aug 2022 --> Jun 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    docetaxel • SHR7390
    almost2years
    Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials. (PubMed, Oncologist)
    SHR7390 0.5 mg plus camrelizumab showed a manageable safety profile. Preliminary clinical activity was reported regardless of MSI and BRAF status.
    P1 data • Journal • MSi-H Biomarker • PD(L)-1 Biomarker
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation • BRAF wild-type
    |
    AiRuiKa (camrelizumab) • SHR7390
    2years
    SHR7390-I-102-AST: The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=31, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=60 --> 31 | Unknown status --> Terminated; Sponsor R & D Strategy Adjustment
    Enrollment change • Trial termination • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • RAS mutation
    |
    AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib) • SHR7390
    3years
    MULAN: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=319, Recruiting, Fudan University | Not yet recruiting --> Recruiting | N=170 --> 319
    Enrollment open • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • PGR positive
    |
    Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR-2554 • SHR7390 • Airui'en (rezvilutamide)
    over4years
    MULAN: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=170, Not yet recruiting, Fudan University
    New P2 trial • BRCA Biomarker • PD(L)-1 Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • PGR positive
    |
    everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR-2554 • SHR7390 • Airui'en (rezvilutamide)